Methods for increasing platelet count by inhibiting biliverdin ixbeta reductase
AssigneeThe Research Foundation for The State University of New York
InventorsWadie F. BAHOU, Song WU
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating a human having a disease or disorder that would benefit from increasing platelet counts. The method involves inhibiting the enzyme activity of biliverdin IXβ reductase (BLVRB) activity or inhibiting the expression of BLVRB gene.
Claims20
A method of treating a subject having a disease or disorder that would benefit from increasing platelet counts, the method comprising administering to the subject therapeutically effective amount of an agent that inhibits biliverdin reductase (BLVRB) enzymatic activity, thereby treating the subject.
A method of treating a subject having a disease or disorder that would benefit from increasing platelet counts, the method comprising administering to the subject therapeutically effective amount of an agent that inhibits the expression of biliverdin IXβ reductase (BLVRB) gene, thereby treating the subject.
A pharmaceutical composition comprising a chemical compound that inhibits the enzymatic activity of BLVRB.
The method of claim 14, wherein the increased breakdown of platelets is caused by one of:
- pregnancy, autoimmune disease, and medications.
A pharmaceutical composition that inhibits the expression of BLVRB gene, the composition comprising a small interfering RNA (siRNA) molecule or an antisense oligonucleotide specific to a region in the mRNA of the BLVRB gene.
Dependencies are inferred from the claim text.